A carregar...
Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease
BACKGROUND: Ustekinumab was approved in Europe for the treatment of adults with moderate to severe Crohn's disease (CD) in 2016, and there is an urgent need for data on its everyday use. AIM: To obtain data on the daily use of ustekinumab. METHODS: This is a retrospective monocentric study. Pat...
Na minha lista:
| Publicado no: | World J Gastroenterol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Baishideng Publishing Group Inc
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6710179/ https://ncbi.nlm.nih.gov/pubmed/31496626 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v25.i31.4481 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|